Skip to Main Content

Daily use of a prescription-grade fish oil pill, first marketed by GlaxoSmithKline before going generic, failed to prevent serious cardiovascular events or death in people with diabetes, according to results from a large clinical trial presented Sunday.

The negative outcome of the study, called ASCEND, adds to the growing body of scientific evidence casting doubt on the long-term heart benefit of products containing omega-3 fatty acids.


It also does no favors for Amarin, which is hoping to upend the emboldened fish oil skepticism when a large cardiovascular outcomes study of its own product Vascepa reads out in September.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.